Intracoronary Compared to Intravenous Bolus Abciximab during Primary Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction (STEMI) Patients Reduces 30-day Mortality and Target Vessel Revascularization: A Randomized Trial

Allan Iversen; Ulrik Abildgaard; Anders Galloe; Peter R Hansen; Soren Galatius; Jan K Madsen; Thomas Engstroem; Sune Ammentorp Haahr-Pedersen; Kurt S Jensen; Jan S Jensen

doi:10.1111/j.1540-8183.2010.00616.x

Intracoronary Compared to Intravenous Bolus Abciximab during Primary Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction (STEMI) Patients Reduces 30-day Mortality and Target Vessel Revascularization: A Randomized Trial

Allan Iversen, Ulrik Abildgaard, Anders Galloe, Peter R Hansen, Soren Galatius, Jan K Madsen, Thomas Engstroem, Sune Ammentorp Haahr-Pedersen, Kurt S Jensen, Jan S Jensen

33 Citations (Scopus)

Abstract

Background: Abciximab is beneficial in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI). However, the optimal administration route of the initial bolus of abciximab, that is, intravenous (IV) versus intracoronary (IC), has been questioned. Preliminary studies suggest that IC-bolus is superior, probably due to high local concentration. In this study, we assess the short-term efficacy and safety of IC compared to IV bolus of abciximab in patients with STEMI during pPCI. Methods: In 2006-2008, we randomized 355 STEMI patients who underwent pPCI and had indication for abciximab to either IV or IC bolus followed by a 12-hour IV infusion. Primary end-points at 30 days were target vessel revascularization (TVR), recurrent myocardial infarction (MI) or death, and the composite of the three. Secondary end-points were bleeding complications. Results: The two groups (IV n = 170;IC n = 185) were similar with respect to baseline characteristics. Mortality at 30 days was 5.3% in the IV group compared to only 1.1% in the IC group (P = 0.02). TVR was performed in 9.4% in the IV group compared to 3.8% in the IC group (P = 0.03). No significant difference in MI rates was seen (IV 4.7% vs. IC 2.7%; P = 0.32). We found a significant reduction in the composite end-point (IV 19.4% vs. IC 7.6%; P = 0.001) in favor of IC use. Major bleeding complications were similar (IV 2.4% vs. IC 1.6%; P = 0.62). Neither difference was observed in minor bleedings (IV 14.1% vs. IC 9.7%; P = 0.20). Conclusion: IC administration of bolus abciximab in STEMI patients undergoing pPCI reduces 30-day mortality and TVR and tends to reduce MI, compared to IV-bolus.

Original language	English
Journal	Journal of Interventional Cardiology
Volume	24
Issue number	2
Pages (from-to)	105-11
Number of pages	7
ISSN	0896-4327
DOIs	https://doi.org/10.1111/j.1540-8183.2010.00616.x
Publication status	Published - 1 Apr 2011

Access to Document

10.1111/j.1540-8183.2010.00616.x

Fingerprint

Dive into the research topics of 'Intracoronary Compared to Intravenous Bolus Abciximab during Primary Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction (STEMI) Patients Reduces 30-day Mortality and Target Vessel Revascularization: A Randomized Trial'. Together they form a unique fingerprint.

Cite this

Iversen, A., Abildgaard, U., Galloe, A., Hansen, P. R., Galatius, S., Madsen, J. K., Engstroem, T., Haahr-Pedersen, S. A., Jensen, K. S., & Jensen, J. S. (2011). Intracoronary Compared to Intravenous Bolus Abciximab during Primary Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction (STEMI) Patients Reduces 30-day Mortality and Target Vessel Revascularization: A Randomized Trial. Journal of Interventional Cardiology, 24(2), 105-11. https://doi.org/10.1111/j.1540-8183.2010.00616.x

Intracoronary Compared to Intravenous Bolus Abciximab during Primary Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction (STEMI) Patients Reduces 30-day Mortality and Target Vessel Revascularization: A Randomized Trial. / Iversen, Allan; Abildgaard, Ulrik; Galloe, Anders et al.

In: Journal of Interventional Cardiology, Vol. 24, No. 2, 01.04.2011, p. 105-11.

Research output: Contribution to journal › Journal article › Research › peer-review

Iversen, A, Abildgaard, U, Galloe, A, Hansen, PR, Galatius, S, Madsen, JK, Engstroem, T, Haahr-Pedersen, SA, Jensen, KS & Jensen, JS 2011, 'Intracoronary Compared to Intravenous Bolus Abciximab during Primary Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction (STEMI) Patients Reduces 30-day Mortality and Target Vessel Revascularization: A Randomized Trial', Journal of Interventional Cardiology, vol. 24, no. 2, pp. 105-11. https://doi.org/10.1111/j.1540-8183.2010.00616.x

Iversen A, Abildgaard U, Galloe A, Hansen PR, Galatius S, Madsen JK et al. Intracoronary Compared to Intravenous Bolus Abciximab during Primary Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction (STEMI) Patients Reduces 30-day Mortality and Target Vessel Revascularization: A Randomized Trial. Journal of Interventional Cardiology. 2011 Apr 1;24(2):105-11. doi: 10.1111/j.1540-8183.2010.00616.x

Iversen, Allan ; Abildgaard, Ulrik ; Galloe, Anders et al. / Intracoronary Compared to Intravenous Bolus Abciximab during Primary Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction (STEMI) Patients Reduces 30-day Mortality and Target Vessel Revascularization: A Randomized Trial. In: Journal of Interventional Cardiology. 2011 ; Vol. 24, No. 2. pp. 105-11.

@article{7cd9aa850a5642cb804b5b6b233591d1,

title = "Intracoronary Compared to Intravenous Bolus Abciximab during Primary Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction (STEMI) Patients Reduces 30-day Mortality and Target Vessel Revascularization: A Randomized Trial",

abstract = "Background: Abciximab is beneficial in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI). However, the optimal administration route of the initial bolus of abciximab, that is, intravenous (IV) versus intracoronary (IC), has been questioned. Preliminary studies suggest that IC-bolus is superior, probably due to high local concentration. In this study, we assess the short-term efficacy and safety of IC compared to IV bolus of abciximab in patients with STEMI during pPCI. Methods: In 2006-2008, we randomized 355 STEMI patients who underwent pPCI and had indication for abciximab to either IV or IC bolus followed by a 12-hour IV infusion. Primary end-points at 30 days were target vessel revascularization (TVR), recurrent myocardial infarction (MI) or death, and the composite of the three. Secondary end-points were bleeding complications. Results: The two groups (IV n = 170;IC n = 185) were similar with respect to baseline characteristics. Mortality at 30 days was 5.3% in the IV group compared to only 1.1% in the IC group (P = 0.02). TVR was performed in 9.4% in the IV group compared to 3.8% in the IC group (P = 0.03). No significant difference in MI rates was seen (IV 4.7% vs. IC 2.7%; P = 0.32). We found a significant reduction in the composite end-point (IV 19.4% vs. IC 7.6%; P = 0.001) in favor of IC use. Major bleeding complications were similar (IV 2.4% vs. IC 1.6%; P = 0.62). Neither difference was observed in minor bleedings (IV 14.1% vs. IC 9.7%; P = 0.20). Conclusion: IC administration of bolus abciximab in STEMI patients undergoing pPCI reduces 30-day mortality and TVR and tends to reduce MI, compared to IV-bolus.",

author = "Allan Iversen and Ulrik Abildgaard and Anders Galloe and Hansen, {Peter R} and Soren Galatius and Madsen, {Jan K} and Thomas Engstroem and Haahr-Pedersen, {Sune Ammentorp} and Jensen, {Kurt S} and Jensen, {Jan S}",

note = "{\textcopyright}2010, Wiley Periodicals, Inc.",

year = "2011",

month = apr,

day = "1",

doi = "10.1111/j.1540-8183.2010.00616.x",

language = "English",

volume = "24",

pages = "105--11",

journal = "Journal of Interventional Cardiology",

issn = "0896-4327",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Intracoronary Compared to Intravenous Bolus Abciximab during Primary Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction (STEMI) Patients Reduces 30-day Mortality and Target Vessel Revascularization: A Randomized Trial

AU - Iversen, Allan

AU - Abildgaard, Ulrik

AU - Galloe, Anders

AU - Hansen, Peter R

AU - Galatius, Soren

AU - Madsen, Jan K

AU - Engstroem, Thomas

AU - Haahr-Pedersen, Sune Ammentorp

AU - Jensen, Kurt S

AU - Jensen, Jan S

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Background: Abciximab is beneficial in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI). However, the optimal administration route of the initial bolus of abciximab, that is, intravenous (IV) versus intracoronary (IC), has been questioned. Preliminary studies suggest that IC-bolus is superior, probably due to high local concentration. In this study, we assess the short-term efficacy and safety of IC compared to IV bolus of abciximab in patients with STEMI during pPCI. Methods: In 2006-2008, we randomized 355 STEMI patients who underwent pPCI and had indication for abciximab to either IV or IC bolus followed by a 12-hour IV infusion. Primary end-points at 30 days were target vessel revascularization (TVR), recurrent myocardial infarction (MI) or death, and the composite of the three. Secondary end-points were bleeding complications. Results: The two groups (IV n = 170;IC n = 185) were similar with respect to baseline characteristics. Mortality at 30 days was 5.3% in the IV group compared to only 1.1% in the IC group (P = 0.02). TVR was performed in 9.4% in the IV group compared to 3.8% in the IC group (P = 0.03). No significant difference in MI rates was seen (IV 4.7% vs. IC 2.7%; P = 0.32). We found a significant reduction in the composite end-point (IV 19.4% vs. IC 7.6%; P = 0.001) in favor of IC use. Major bleeding complications were similar (IV 2.4% vs. IC 1.6%; P = 0.62). Neither difference was observed in minor bleedings (IV 14.1% vs. IC 9.7%; P = 0.20). Conclusion: IC administration of bolus abciximab in STEMI patients undergoing pPCI reduces 30-day mortality and TVR and tends to reduce MI, compared to IV-bolus.

AB - Background: Abciximab is beneficial in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI). However, the optimal administration route of the initial bolus of abciximab, that is, intravenous (IV) versus intracoronary (IC), has been questioned. Preliminary studies suggest that IC-bolus is superior, probably due to high local concentration. In this study, we assess the short-term efficacy and safety of IC compared to IV bolus of abciximab in patients with STEMI during pPCI. Methods: In 2006-2008, we randomized 355 STEMI patients who underwent pPCI and had indication for abciximab to either IV or IC bolus followed by a 12-hour IV infusion. Primary end-points at 30 days were target vessel revascularization (TVR), recurrent myocardial infarction (MI) or death, and the composite of the three. Secondary end-points were bleeding complications. Results: The two groups (IV n = 170;IC n = 185) were similar with respect to baseline characteristics. Mortality at 30 days was 5.3% in the IV group compared to only 1.1% in the IC group (P = 0.02). TVR was performed in 9.4% in the IV group compared to 3.8% in the IC group (P = 0.03). No significant difference in MI rates was seen (IV 4.7% vs. IC 2.7%; P = 0.32). We found a significant reduction in the composite end-point (IV 19.4% vs. IC 7.6%; P = 0.001) in favor of IC use. Major bleeding complications were similar (IV 2.4% vs. IC 1.6%; P = 0.62). Neither difference was observed in minor bleedings (IV 14.1% vs. IC 9.7%; P = 0.20). Conclusion: IC administration of bolus abciximab in STEMI patients undergoing pPCI reduces 30-day mortality and TVR and tends to reduce MI, compared to IV-bolus.

U2 - 10.1111/j.1540-8183.2010.00616.x

DO - 10.1111/j.1540-8183.2010.00616.x

M3 - Journal article

C2 - 21175845

SN - 0896-4327

VL - 24

SP - 105

EP - 111

JO - Journal of Interventional Cardiology

JF - Journal of Interventional Cardiology

IS - 2

ER -